Advanced search
Publication Cover
Expert Opinion on Drug Metabolism & Toxicology Volume 12, 2016 - Issue 1
Submit an article Journal homepage
333
Views
7
CrossRef citations to date
0
Altmetric
Reviews

Pharmacodynamic considerations in the treatment of pulmonary hypertension in infants: challenges and future perspectives

U KraemerIntensive Care and Department of Pediatric Surgery, Erasmus Medical Center, Sophia Children’s Hospital, NL-3000 CBRotterdam, the NetherlandsCorrespondence[email protected]
,
S Cochius-den OtterIntensive Care and Department of Pediatric Surgery, Erasmus Medical Center, Sophia Children’s Hospital, NL-3000 CBRotterdam, the Netherlands
,
KG SnoekIntensive Care and Department of Pediatric Surgery, Erasmus Medical Center, Sophia Children’s Hospital, NL-3000 CBRotterdam, the Netherlands
&
D TibboelIntensive Care and Department of Pediatric Surgery, Erasmus Medical Center, Sophia Children’s Hospital, NL-3000 CBRotterdam, the Netherlands
Pages 1-19 | Published online: 26 Nov 2015

Bibliography

  • Papers of special note have been highlighted as either of interest (•) or of considerable interest (••) to readers.
  • Ivy DD, Abman SH, Barst RJ, et al. Pediatric pulmonary hypertension. J Am Coll Cardiol. 2013;62(25 Suppl.):D117–D26.

•• Excellent review article of pulmonary hypertension in children.

  • Galie N, Hoeper MM, Humbert M, et al. Guidelines for the diagnosis and treatment of pulmonary hypertension: the task force for the diagnosis and treatment of pulmonary hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS), endorsed by the International Society of Heart and Lung Transplantation (ISHLT). Eur Heart J. 2009;30(20):2493–2537.

•• Recent guidelines for pulmonary hypertension management.

  • Abman SH, Ivy DD. Recent progress in understanding pediatric pulmonary hypertension. Curr Opin Pediatr. 2011;23(3):298–304.
  • Haworth SG. Pulmonary hypertension in the young. Heart. 2002;88(6):658–664.
  • Kool H, Mous D, Tibboel D, et al. Pulmonary vascular development goes awry in congenital lung abnormalities. Birth Defects Res C Embryo Today. 2014;102(4):343–358.
  • Keller RL, Tacy TA, Hendricks-Munoz K, et al. Congenital diaphragmatic hernia: endothelin-1, pulmonary hypertension, and disease severity. Am J Respir Crit Care Med. 2010;182(4):555–561.
  • Lutz J, Gorenflo M, Habighorst M, et al. Endothelin-1- and endothelin-receptors in lung biopsies of patients with pulmonary hypertension due to congenital heart disease. Clin Chem Lab Med. 1999;37(4):423–428.
  • Gien J, Tseng N, Seedorf G, et al. Endothelin-1 impairs angiogenesis in vitro through Rho-kinase activation after chronic intrauterine pulmonary hypertension in fetal sheep. Pediatr Res. 2013;73(3):252–262.
  • Rondelet B, Kerbaul F, Motte S, et al. Bosentan for the prevention of overcirculation-induced experimental pulmonary arterial hypertension. Circulation. 2003;107(9):1329–1335.
  • Nagendran J, Archer SL, Soliman D, et al. Phosphodiesterase type 5 is highly expressed in the hypertrophied human right ventricle, and acute inhibition of phosphodiesterase type 5 improves contractility. Circulation. 2007;116(3):238–248.
  • Simonneau G, Gatzoulis MA, Adatia I, et al. Updated clinical classification of pulmonary hypertension. J Am Coll Cardiol. 2013;62(25 Suppl):D34–41.
  • Berger RM, Beghetti M, Humpl T, et al. Clinical features of paediatric pulmonary hypertension: a registry study. Lancet. 2012;379(9815):537–546.

• Results of the Tracking Outcomes and Practice in Pediatric Pulmonary Hypertension (TOPP) registry since its start in 2008.

  • Moledina S, Hislop AA, Foster H, et al. Childhood idiopathic pulmonary arterial hypertension: a national cohort study. Heart. 2010;96(17):1401–1406.
  • Fraisse A, Jais X, Schleich JM, et al. Characteristics and prospective 2-year follow-up of children with pulmonary arterial hypertension in France. Arch Cardiovasc Dis. 2010;103(2):66–74.
  • Walsh-Sukys MC, Tyson JE, Wright LL, et al. Persistent pulmonary hypertension of the newborn in the era before nitric oxide: practice variation and outcomes. Pediatrics. 2000;105(1 Pt 1):14–20.
  • McLaughlin VV, McGoon MD. Pulmonary arterial hypertension. Circulation. 2006;114(13):1417–1431.
  • Ghofrani HA, Humbert M. The role of combination therapy in managing pulmonary arterial hypertension. Eur Respir Rev. 2014;23(134):469–475.
  • Furchgott RF. Endothelium-derived relaxing factor: discovery, early studies, and identification as nitric oxide. Biosci Rep. 1999;19(4):235–251.
  • Pepke-Zaba J, Higenbottam TW, Dinh-Xuan AT, et al. Inhaled nitric oxide as a cause of selective pulmonary vasodilatation in pulmonary hypertension. Lancet. 1991;338(8776):1173–1174.
  • Ichinose F, Roberts Jr. JD, Zapol WM. Inhaled nitric oxide: a selective pulmonary vasodilator: current uses and therapeutic potential. Circulation. 2004;109(25):3106–3111.
  • Finer NN, Barrington KJ. Nitric oxide for respiratory failure in infants born at or near term. Cochrane Database Syst Rev. 2006;4:CD000399.
  • Ehrenkranz RA. Inhaled nitric oxide in full-term and nearly full-term infants with hypoxic respiratory failure. New Engl J Med. 1997;336(9):597–604.
  • Golombek SG, Young JN. Efficacy of inhaled nitric oxide for hypoxic respiratory failure in term and late preterm infants by baseline severity of illness: a pooled analysis of three clinical trials. Clin Ther. 2010;32(5):939–948.
  • Reiss I, Schaible T, van den Hout L, et al. Standardized postnatal management of infants with congenital diaphragmatic hernia in Europe: the CDH EURO Consortium consensus. Neonatology. 2010;98(4):354–364.
  • Malowitz JR, Hornik CP, Laughon MM, et al. Management practice and mortality for infants with congenital diaphragmatic hernia. Am J Perinatol. 2015;32(9):887–894.
  • Campbell BT, Herbst KW, Briden KE, et al. Inhaled nitric oxide use in neonates with congenital diaphragmatic hernia. Pediatrics. 2014;134(2):e420–6.
  • Shehata SM, Sharma HS, Mooi WJ, et al. Pulmonary hypertension in human newborns with congenital diaphragmatic hernia is associated with decreased vascular expression of nitric-oxide synthase. Cell Biochem Biophys. 2006;44(1):147–155.
  • Karamanoukian HL, Peay T, Love JE, et al. Decreased pulmonary nitric oxide synthase activity in the rat model of congenital diaphragmatic hernia. J Pediatr Surg. 1996;31(8):1016–1019.
  • Aikio O, Metsola J, Vuolteenaho R, et al. Transient defect in nitric oxide generation after rupture of fetal membranes and responsiveness to inhaled nitric oxide in very preterm infants with hypoxic respiratory failure. J Pediatr. 2012;161(3):397-403.e1.
  • Barrington KJ, Finer N. Inhaled nitric oxide for respiratory failure in preterm infants. Cochrane Database Syst Rev. 2010;12:CD000509.
  • Bizzarro M, Gross I. Inhaled nitric oxide for the postoperative management of pulmonary hypertension in infants and children with congenital heart disease. Cochrane Database Syst Rev. 2005;4:CD005055.
  • Bizzarro M, Gross I, Barbosa FT. Inhaled nitric oxide for the postoperative management of pulmonary hypertension in infants and children with congenital heart disease review. Cochrane Database Syst Rev. 2014;7:CD005055.
  • Miller O, Tang SF, Keech A, et al. Inhaled nitric oxide and prevention of pulmonary hypertension after congenital heart surgery: a randomised double-blind study. Lancet. 2000;356(9240):1464–1469.
  • Adatia I, Beghetti M. Early postoperative care of patients with pulmonary hypertension associated with congenital cardiac disease. Cardiol Young. 2009;19(4):315–319.
  • Namachivayam P, Theilen U, Butt WW, et al. Sildenafil prevents rebound pulmonary hypertension after withdrawal of nitric oxide in children. Am J Respir Crit Care Med. 2006;174(9):1042–1047.

• First study over the prevention of rebound-PH after weaning from inhaled NO through a single dose of sildenafil.

  • Smith HA, Canter JA, Christian KG, et al. Nitric oxide precursors and congenital heart surgery: a randomized controlled trial of oral citrulline. J Thorac Cardiovasc Surg. 2006;132(1):58–65.
  • Loukanov T, Bucsenez D, Springer W, et al. Comparison of inhaled nitric oxide with aerosolized iloprost for treatment of pulmonary hypertension in children after cardiopulmonary bypass surgery. Clin Res Cardiol. 2011;100(7):595–602.
  • Gorenflo M, Gu H, Xu Z. Peri-operative pulmonary hypertension in paediatric patients: current strategies in children with congenital heart disease. Cardiology. 2010;116(1):10–17.
  • Konduri GG, Solimano A, Sokol GM, et al. A randomized trial of early versus standard inhaled nitric oxide therapy in term and near-term newborn infants with hypoxic respiratory failure. Pediatrics. 2004;113(3 Pt 1):559–564.
  • Sadiq HF, Mantych G, Benawra RS, et al. Inhaled nitric oxide in the treatment of moderate persistent pulmonary hypertension of the newborn: a randomized controlled, multicenter trial. J Perinatol. 2003;23(2):98–103.
  • Stocker C, Penny DJ, Brizard CP, et al. Intravenous sildenafil and inhaled nitric oxide: a randomised trial in infants after cardiac surgery. Intensive Care Med. 2003;29(11):1996–2003.
  • Finer NN, Sun JW, Rich W, et al. Randomized, prospective study of low-dose versus high-dose inhaled nitric oxide in the neonate with hypoxic respiratory failure. Pediatrics. 2001;108(4):949–955.
  • Clark RH, Kueser TJ, Walker MW, et al. Low-dose nitric oxide therapy for persistent pulmonary hypertension of the newborn. New Engl J Med. 2000;342(7):469–474.
  • Day RW, Hawkins JA, McGough EC, et al. Randomized controlled study of inhaled nitric oxide after operation for congenital heart disease. Ann Thorac Surg. 2000;69(6):1907–1913.
  • Morris K, Beghetti M, Petros A, et al. Comparison of hyperventilation and inhaled nitric oxide for pulmonary hypertension after repair of congenital heart disease. Crit Care Med. 2000;28(8):2974–2978.
  • Cornfield DN, Maynard RC, DeRegnier RO, et al. Randomized, controlled trial of low-dose inhaled nitric-oxide in the treatment of term and near-term infants with respiratory failure and pulmonary hypertension. Pediatrics. 1999;104(5 I):1089–1094.
  • Wood KS, McCaffrey MJ, Donovan JC, et al. Effect of initial nitric oxide concentration on outcome in infants with persistent pulmonary hypertension of the newborn. Biol Neonate. 1999;75(4):215–224.
  • Davidson D, Barefield ES, Kattwinkel J, et al. Inhaled nitric oxide for the early treatment of persistent pulmonary hypertension of the term newborn: a randomized, double-masked, placebo- controlled, dose-response, multicenter study. Pediatrics. 1998;101(3 I):325–334.
  • Kinsella JP, Truog WE, Walsh WF, et al. Randomized, multicenter trial of inhaled nitric oxide and high-frequency oscillatory ventilation in severe, persistent pulmonary hypertension of the newborn. J Pediatr. 1997;131(1 I):55–62.
  • Roberts JD Jr., Fineman JR, Morin FC 3rd, et al. Inhaled nitric oxide and persistent pulmonary hypertension of the newborn. The inhaled nitric oxide study group. N Engl J Med. 1997;336(9):605–610.
  • Wessel DL, Adatia I, Van Marter LJ, et al. Improved oxygenation in a randomized trial of inhaled nitric oxide for persistent pulmonary hypertension of the newborn. Pediatrics. 1997;100(5):E7.
  • Goldman AP, Delius RE, Deanfield JE, et al. Nitric oxide is superior to prostacyclin for pulmonary hypertension after cardiac operations. Ann Thorac Surg. 1995;60(2):300–306.
  • Barst RJ, Ivy DD, Gaitan G, et al. A randomized, double-blind, placebo-controlled, dose-ranging study of oral sildenafil citrate in treatment-naive children with pulmonary arterial hypertension. Circulation. 2012;125(2):324–334.
  • Barst RJ, Beghetti M, Pulido T, et al. STARTS-2: long-term survival with oral sildenafil monotherapy in treatment-naive pediatric pulmonary arterial hypertension. Circulation. 2014;129(19):1914–1923.

•• Results of the STARTS-2 study. This study resulted in the FDA warning concerning the use of sildenafil in small children.

  • Martell M, Blasina F, Silvera F, et al. Intratracheal sildenafil in the newborn with pulmonary hypertension. Pediatrics. 2007;119(1):215–216. author reply 6.
  • Samiee-Zafarghandy S, Smith PB, Van Den Anker JN. Safety of sildenafil in infants. Pediatr Crit Care Med. 2014;15(4):362–368.
  • Mukherjee A, Dombi T, Wittke B, et al. Population pharmacokinetics of sildenafil in term neonates: evidence of rapid maturation of metabolic clearance in the early postnatal period. Clin Pharmacol Ther. 2009;85(1):56–63.
  • Steinhorn RH, Kinsella JP, Pierce C, et al. Intravenous sildenafil in the treatment of neonates with persistent pulmonary hypertension. J Pediatr. 2009;155(6):841–7.e1.
  • Ahsman MJ, Witjes BC, Wildschut ED, et al. Sildenafil exposure in neonates with pulmonary hypertension after administration via a nasogastric tube. Arch Dis Child Fetal Neonatal Ed. 2010;95(2):F109–F14.
  • Shah PS, Ohlsson A. Sildenafil for pulmonary hypertension in neonates. Cochrane Database Syst Rev. 2011;8:CD005494.
  • Baquero H, Soliz A, Neira F, et al. Oral sildenafil in infants with persistent pulmonary hypertension of the newborn: a pilot randomized blinded study. Pediatrics. 2006;117(4):1077–1083.
  • Vargas-Origel A, Gomez-Rodriguez G, Aldana-Valenzuela C, et al. The use of sildenafil in persistent pulmonary hypertension of the newborn. Am J Perinatol. 2010;27(3):225–230.
  • Shah PS, Ohlsson A. Sildenafil for pulmonary hypertension in neonates. Cochrane Database Syst Rev. 2007;(3):CD005494.
  • Uslu S, Kumtepe S, Bulbul A, et al. A comparison of magnesium sulphate and sildenafil in the treatment of the newborns with persistent pulmonary hypertension: a randomized controlled trial. J Trop Pediatr. 2011;57(4):245–250.
  • Vassalos A, Peng E, Young D, et al. Pre-operative sildenafil and pulmonary endothelial-related complications following cardiopulmonary bypass: a randomised trial in children undergoing cardiac surgery. Anaesthesia. 2011;66(6):472–480.
  • El Midany AA, Mostafa EA, Azab S, et al. Perioperative sildenafil therapy for pulmonary hypertension in infants undergoing congenital cardiac defect closure. Interact Cardiovasc Thorac Surg. 2013;17(6):963–968.
  • Fraisse A, Butrous G, Taylor MB, et al. Intravenous sildenafil for postoperative pulmonary hypertension in children with congenital heart disease. Intensive Care Med. 2011;37(3):502–509.
  • Marsh CS, Marden B, Newsom R. Severe retinopathy of prematurity (ROP) in a premature baby treated with sildenafil acetate (Viagra) for pulmonary hypertension. Br J Ophthalmol. 2004;88(2):306–307.
  • Pierce CM, Petros AJ, Fielder AR. No evidence for severe retinopathy of prematurity following sildenafil. Br J Ophthalmol. 2005;89(2):250.
  • Fang AY, Guy KJ, Konig K. The effect of sildenafil on retinopathy of prematurity in very preterm infants. J Perinatol. 2013;33(3):218–221.
  • Kehat R, Bonsall DJ, North R, et al. Ocular findings of oral sildenafil use in term and near-term neonates. J AAPOS. 2010;14(2):159–162.
  • Tan K, Krishnamurthy MB, O’Heney JL, et al. Sildenafil therapy in bronchopulmonary dysplasia-associated pulmonary hypertension: a retrospective study of efficacy and safety. Eur J Pediatr. 2015;174(8):1109–1115.
  • Fawzi AA, Chou JC, Kim GA, et al. Sildenafil attenuates vaso-obliteration and neovascularization in a mouse model of retinopathy of prematurity. Invest Ophthalmol Vis Sci. 2014;55(3):1493–1501.
  • Steiner M, Salzer U, Baumgartner S, et al. Intravenous sildenafil i.v. as rescue treatment for refractory pulmonary hypertension in extremely preterm infants. Klin Padiatr. 2014;226(4):211–215.
  • Noori S, Friedlich P, Wong P, et al. Cardiovascular effects of sildenafil in neonates and infants with congenital diaphragmatic hernia and pulmonary hypertension. Neonatology. 2007;91(2):92–100.
  • Bialkowski A, Moenkemeyer F, Patel N. Intravenous sildenafil in the management of pulmonary hypertension associated with congenital diaphragmatic hernia. Eur J Pediatr Surg. 2015;25(2):171–176.
  • Mourani PM, Sontag MK, Ivy DD, et al. Effects of long-term sildenafil treatment for pulmonary hypertension in infants with chronic lung disease. J Pediatr. 2009;154(3):379–84.e2.
  • Nyp M, Sandritter T, Poppinga N, et al. Sildenafil citrate, bronchopulmonary dysplasia and disordered pulmonary gas exchange: any benefits? J Perinatol. 2012;32(1):64–69.
  • Ilbawi MN, Idriss FS, DeLeon SY, et al. Hemodynamic effects of intravenous nitroglycerin in pediatric patients after heart surgery. Circulation. 1985;72(3 Pt 2):II101–7.
  • Singh R, Choudhury M, Saxena A, et al. Inhaled nitroglycerin versus inhaled milrinone in children with congenital heart disease suffering from pulmonary artery hypertension. J Cardiothorac Vasc Anesth. 2010;24(5):797–801.
  • Goyal P, Kiran U, Chauhan S, et al. Efficacy of nitroglycerin inhalation in reducing pulmonary arterial hypertension in children with congenital heart disease. Br J Anaesth. 2006;97(2):208–214.
  • Yurtseven N, Karaca P, Kaplan M, et al. Effect of nitroglycerin inhalation on patients with pulmonary hypertension undergoing mitral valve replacement surgery. Anesthesiology. 2003;99(4):855–858.
  • Ghofrani HA, D’Armini AM, Grimminger F, et al. Riociguat for the treatment of chronic thromboembolic pulmonary hypertension. N Engl J Med. 2013;369(4):319–329.
  • Ghofrani HA, Galie N, Grimminger F, et al. Riociguat for the treatment of pulmonary arterial hypertension. N Engl J Med. 2013;369(4):330–340.

• Results of a member of a new class of PH treatment (soluble guanylate cyclase stimulators) in adults.

  • Fraisse A, Butrous G, Taylor MB, et al. Intravenous sildenafil for postoperative pulmonary hypertension in children with congenital heart disease. Intensive Care Med. 2011;37(3):502–509.
  • Steinhorn RH. Diagnosis and treatment of pulmonary hypertension in infancy. Early Hum Dev. 2013;89(11):865–874..

• Comprehensive review focusing on the special problems of diagnosing and treating infants with PH.

  • Steinhorn RH, Kusic-Pajic A, Cornelisse P, et al. Bosentan as adjunctive therapy for persistent pulmonary hypertension of the newborn: results of the future-4 study. Circulation. 2014;Abstract 13503
  • Chen SJ, Chen YF, Meng QC, et al. Endothelin-receptor antagonist bosentan prevents and reverses hypoxic pulmonary hypertension in rats. J Appl Physiol (1985). 1995;79(6):2122–2131.
  • LaDouceur DM, Flynn MA, Keiser JA, et al. ETA and ETB receptors coexist on rabbit pulmonary artery vascular smooth muscle mediating contraction. Biochem Biophys Res Commun. 1993;196(1):209–215.
  • Vorhies EE, Ivy DD. Drug treatment of pulmonary hypertension in children. Pediatr Drugs. 2014;16(1):43–65.
  • Taguchi M, Ichida F, Hirono K, et al. Pharmacokinetics of bosentan in routinely treated Japanese pediatric patients with pulmonary arterial hypertension. Drug Metab Pharmacokinet. 2011;26(3):280–287.
  • Beghetti M. Bosentan in pediatric patients with pulmonary arterial hypertension review. Curr Vasc Pharmacol. 2009;7(2):225–233.
  • Beghetti M, Haworth SG, Bonnet D, et al. Pharmacokinetic and clinical profile of a novel formulation of bosentan in children with pulmonary arterial hypertension: the FUTURE-1 study. Br J Clin Pharmacol. 2009;68(6):948–955.
  • Mohamed WA, Ismail M. A randomized, double-blind, placebo-controlled, prospective study of bosentan for the treatment of persistent pulmonary hypertension of the newborn. J Perinatol. 2012;32(8):608–613.
  • Maxey DM, Ivy DD, Ogawa MT, et al. Food and drug administration (FDA) postmarket reported side effects and adverse events associated with pulmonary hypertension therapy in pediatric patients. Pediatr Cardiol. 2013;34(7):1628–1636.

• Analysis of the registered adverse events and side effects using FDA data of the commonly used PH medication.

  • Beghetti M, Hoeper MM, Kiely DG, et al. Safety experience with bosentan in 146 children 2-11 years old with pulmonary arterial hypertension: results from the European Postmarketing Surveillance program. Pediatr Res. 2008;64(2):200–204.
  • Sasaki T, Nemoto S, Ozawa H, et al. Use of bosentan hydrate, an endothelin-1 dual receptor blocker, for treatment of impaired pulmonary circulation after congenital cardiac surgery. Cardiol Young. 2010;20:324–325.
  • Ling Y, Shen XD, Guo SX. Assessment of the effect of bosentan in the treatment of pulmonary hypertension early after congenital cardiac surgery in infants. Cardiology. 2009;114:111–112.
  • Ren R, He F, Xiao X. Bosentan treatment for pulmonary arterial hypertension due to complete atrioventricular septal defect in an infant with Down’s syndrome. Int J Cardiol. 2014;177(3):1054–1055.
  • Hirono K, Yoshimura N, Taguchi M, et al. Bosentan induces clinical and hemodynamic improvement in candidates for right-sided heart bypass surgery. J Thorac Cardiovasc Surg. 2010;140(2):346–351.
  • Maiya S, Hislop AA, Flynn Y, et al. Response to bosentan in children with pulmonary hypertension. Heart. 2006;92(5):664–670.
  • Marseglia L, Pellegrino S, Calabro MP, et al. Combined oral sildenafil and bosentan in an ex preterm infant with bronchopulmonary dysplasia, sepsis and severe pulmonary arterial hypertension refractory to inhaled nitric oxide. Exp Clin Cardiol. 2014;20(6):145–148.
  • Goissen C, Ghyselen L, Tourneux P, et al. Persistent pulmonary hypertension of the newborn with transposition of the great arteries: successful treatment with bosentan. Eur J Pediatr. 2008;167(4):437–440.
  • Wagenaar GT, De Visser YP, Laghmani E, et al. Ambrisentan prolongs survival by attenuating pulmonary hypertension, fibrin deposition and right ventricular hypertrophy in neonatal hyperoxic lung injury. Am J Respir Crit Care Med. 2011;183:A3941.
  • Takatsuki S, Rosenzweig EB, Zuckerman W, et al. Clinical safety, pharmacokinetics, and efficacy of ambrisentan therapy in children with pulmonary arterial hypertension. Pediatr Pulmonol. 2013;48(1):27–34.
  • Bos CL, Richel DJ, Ritsema T, et al. Prostanoids and prostanoid receptors in signal transduction. Int J Biochem Cell Biol. 2004;36(7):1187–1205.
  • Putensen C, Hormann C, Kleinsasser A, et al. Cardiopulmonary effects of aerosolized prostaglandin E1 and nitric oxide inhalation in patients with acute respiratory distress syndrome. Am J Respir Crit Care Med. 1998;157(6 Pt 1):1743–1747.
  • Olschewski H, Simonneau G, Galie N, et al. Inhaled iloprost for severe pulmonary hypertension. N Engl J Med. 2002;347(5):322–329.
  • Fuller BM, Mohr NM, Skrupky L, et al. The use of inhaled prostaglandins in patients with acute respiratory distress syndrome: a systematic review and meta-analysis. Chest. 2015;147(6):1510–1522.
  • Chaumais MC, Jobard M, Huertas A, et al. Pharmacokinetic evaluation of continuous intravenous epoprostenol. Expert Opin Drug Metab Toxicol. 2010;6(12):1587–1598.
  • Sood BG, Keszler M, Garg M, et al. Inhaled PGE1 in neonates with hypoxemic respiratory failure: two pilot feasibility randomized clinical trials. Trials. 2014;15(1):486.
  • Kahveci H, Yilmaz O, Avsar UZ, et al. Oral sildenafil and inhaled iloprost in the treatment of pulmonary hypertension of the newborn. Pediatr Pulmonol. 2014;49(12):1205–1213.
  • Bassler D, Kreutzer K, McNamara P, et al. Milrinone for persistent pulmonary hypertension of the newborn review. Cochrane Database Syst Rev. 2010;11:CD007802.
  • Mc Namara PJ, Shivananda SP, Sahni M, et al. Pharmacology of milrinone in neonates with persistent pulmonary hypertension of the newborn and suboptimal response to inhaled nitric oxide*. Pediatr Crit Care Med. 2013;14(1):74–84.
  • McNamara PJ, Laique F, Muang-In S, et al. Milrinone improves oxygenation in neonates with severe persistent pulmonary hypertension of the newborn. J Crit Care. 2006;21(2):217–222.
  • James AT, Bee C, Corcoran JD, et al. Treatment of premature infants with pulmonary hypertension and right ventricular dysfunction with milrinone: a case series. J Perinatol. 2015;35(4):268–273.
  • Bassler D, Choong K, McNamara P, et al. Neonatal persistent pulmonary hypertension treated with milrinone: four case reports. Biol Neonate. 2006;89(1):1–5.
  • Tzialla C, Cerbo RM, Perotti G. Persistent pulmonary hypertension of the newborn refractory to inhaled nitric oxide-treated with milrinone: a case report: turkishjournalpediatrics.org; 2010.
  • Patel N. Use of milrinone to treat cardiac dysfunction in infants with pulmonary hypertension secondary to congenital diaphragmatic hernia: a review of six patients. Neonatology. 2012;102(2):130–136.

• A paper focusing on echocardiography in monitoring the effects of milrinone in PH.

  • Samiee-Zafarghandy S, Raman SR, van den Anker JN, et al. Safety of milrinone use in neonatal intensive care units. Early Hum Dev. 2015;91(1):31–35.
  • Gurakan B, Kayiran P, Ozturk N, et al. Therapeutic combination of sildenafil and iloprost in a preterm neonate with pulmonary hypertension. Pediatr Pulmonol. 2011;46(6):617–620.
  • Filan PM, McDougall PN, Shekerdemian LS. Combination pharmacotherapy for severe neonatal pulmonary hypertension. J Paediatr Child Health. 2006;42(4):219–220.
  • Radicioni M, Bruni A, Camerini P. Combination therapy for life-threatening pulmonary hypertension in a premature infant: first report on bosentan use. Eur J Pediatr. 2011;170(8):1075–1078.
  • Shekerdemian LS, Ravn HB, Penny DJ. Interaction between inhaled nitric oxide and intravenous sildenafil in a porcine model of meconium aspiration syndrome. Pediatr Res. 2004;55(3):413–418.
  • Nir A, Lindinger A, Rauh M, et al. NT-pro-B-type natriuretic peptide in infants and children: reference values based on combined data from four studies. Pediatr Cardiol. 2009;30(1):3–8.

• A paper over reference values for NT-pro BNP levels in normal infants and children. The data were obtained from four studies.

  • Cuna A, Kandasamy J, Sims B. B-type natriuretic peptide and mortality in extremely low birth weight infants with pulmonary hypertension: a retrospective cohort analysis. BMC Pediatr. 2014;14:68.
  • Mourani PM, Sontag MK, Younoszai A, et al. Early pulmonary vascular disease in preterm infants at risk for bronchopulmonary dysplasia. Am J Respir Crit Care Med. 2015;191(1):87–95.
  • Ploegstra MJ, Roofthooft MT, Douwes JM, et al. Echocardiography in pediatric pulmonary arterial hypertension: early study on assessing disease severity and predicting outcome. Circ Cardiovasc Imaging. 2014;8(1):pii: e000878.
  • Jone PN, Ivy DD. Echocardiography in pediatric pulmonary hypertension. Front Pediatr. 2014;2:124.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.